October 24, 2013
Plandaí Preparing for Strong 2014
It is that time of year again. With about ten weeks left in calendar year 2013, investors and management teams alike are turning toward 2014 and the grand prospects that lie ahead, and Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.51 – Spec Buy) is no exception. The Company has a series of development milestones and clinical trials scheduled to conclude or commence this quarter and early next year, which will serve as a catalyst for meaningful revenue generation in 2014.
For example, Plandaí is already in the midst of a key, clinical study to determine the absorption level of its
Phytofare™ Pheroid™ Topical Catechin Complex when used in topical creams and solutions. Another trial seeks to confirm the anti-inflammatory characteristics and properties inherent in the use of the same product with topical creams to reduce irritation and inflammation. Results of both trials are slated to be released in the early part of 2014.
Other fourth quarter 2013 human trials that should have a direct impact on revenue in 2014 include a 90-subject weight loss trial utilizing the Company’s flagship product, and a trial to measure the effectiveness of Phytofare™ Limonoid Glycoside Complex cold and flu treatment.
In early 2014, the Company will launch a trial to test anti-aging properties of its topical cream delivered offering. Solid results from this trial should result in a landmark transaction for the Company with Oasix, Inc., a Canadian company that develops and markets skin care products and also operates the Oasis Skin Institute in Alberta, Canada. Not only would it trigger the balance of an earlier agreed upon total initial payment of $500,000, but due to a 5-year license agreement with Oasix, minimum quantity purchases of the Topical Catechin Complex from Plandaí for use in multiple skin care products, will commence.
With the conclusion of these trials and a new Phytofare human bioavailability study in 1Q14, Plandaí is making the transition from a pure research and development firm to an R&D-based firm that is able to generate meaningful commercial revenue in the key segments of the lucrative nutraceutucal industry. This shift will be clearly evident in the first half of 2014, and will likely be reflected in a rise in market value and the stock price, well ahead of these milestone events.
For more information, refer to our previous sponsored PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com